Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
PURPOSE: Phase I trial to determine the effectiveness of thalidomide in treating patients who
have asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.